TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study
Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Caron A. Jacobson(Dana-Farber Cancer Institute), Asad Bashey, Haesook T. Kim(Dana-Farber Cancer Institute), Karen Francoeur(Dana-Farber Cancer Institute), Jens Rueter(Jackson Laboratory), Adam Boruchov(St. Francis Medical Center), Alyssa Nicotra(Dana-Farber Cancer Institute), Peter Sportelli(CDG Therapeutics (United States)), David C. Fisher(Dana-Farber Cancer Institute), Laura Stampleman, Hari P. Miskin(CDG Therapeutics (United States)), Alexandra Savell(Dana-Farber Cancer Institute), Jeffrey Hellman(Dana-Farber Cancer Institute)
Cited by 15
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k